Universal cancer vaccine

References

• Lokhov PG, Balashova EE. Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro. Hum Vaccin Immunother 2013; 9:198 - 209; PMID: 23442592
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006; 25:297 - 319; http://dx.doi.org/10.1080/08830180600992472; PMID: 17169778
   PubMed Web of Science ®Google Scholar
• Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6:1160 - 6; http://dx.doi.org/10.1038/80506; PMID: 11017149
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Nolan GP. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 2003; 23:2B 1165 - 72; PMID: 12820367
   PubMed Web of Science ®Google Scholar
• Corsini E, Gelati M, Calatozzolo C, Alessandri G, Frigerio S, De Francesco M, et al. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother 2004; 53:955 - 62; http://dx.doi.org/10.1007/s00262-004-0529-5; PMID: 15449042
   PubMedGoogle Scholar
• Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95:85 - 90; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03175.x; PMID: 14720332
   PubMed Web of Science ®Google Scholar
• Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, et al. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 2006; 12:5834 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-06-1105; PMID: 17020991
   PubMed Web of Science ®Google Scholar
• Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, et al. Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32:363 - 70; http://dx.doi.org/10.1016/j.ejso.2006.01.016; PMID: 16520018
   PubMed Web of Science ®Google Scholar
• Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191:795 - 804; http://dx.doi.org/10.1084/jem.191.5.795; PMID: 10704461
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850 - 4; http://dx.doi.org/10.1126/science.1076514; PMID: 12242449
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372 - 7; http://dx.doi.org/10.1073/pnas.1533209100; PMID: 12826605
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005 - 16; http://dx.doi.org/10.1245/ASO.2005.03.536; PMID: 16283570
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043 - 53; http://dx.doi.org/10.1200/JCO.2005.06.205; PMID: 16087944
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630 - 41; http://dx.doi.org/10.1038/nri1150; PMID: 12974478
   PubMed Web of Science ®Google Scholar
• Hart MN, Sadewasser KL, Cancilla PA, DeBault LE. Experimental autoimmune type of vasculitis resulting from activation of mouse lymphocytes to cultured endothelium. Lab Invest 1983; 48:419 - 27; PMID: 6834786
   PubMed Web of Science ®Google Scholar
• Matsuda M. Experimental glomerular tissue injury induced by immunization with cultured endothelial cell plasma membrane. Acta Pathol Jpn 1988; 38:823 - 39; PMID: 3055806
   PubMedGoogle Scholar
• Thompson PL, Dessureault S. In: Shurin MR, Smolkin YS, editors. Immune-Mediated Diseases From Theory to Therapy New York: Springer; 2007. p. 345-55.
   Google Scholar
• de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57:1569 - 77; http://dx.doi.org/10.1007/s00262-008-0536-z; PMID: 18523771
   PubMed Web of Science ®Google Scholar
• Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010; 22:132 - 43; http://dx.doi.org/10.1016/j.smim.2010.02.004; PMID: 20356763
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Lang JM, Andrei AC, McNeel DG. Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines 2009; 8:1657 - 61; http://dx.doi.org/10.1586/erv.09.134; PMID: 19943761
   PubMed Web of Science ®Google Scholar
• Lokhov PG, Balashova EE. Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens. J Cancer 2010; 1:230 - 41; http://dx.doi.org/10.7150/jca.1.230; PMID: 21151581
   PubMedGoogle Scholar
• Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell surface proteins stimulate a cytotoxic immune response against tumor-activated endothelial cells in vitro. J Cancer Sci Ther. 2010; 2:126 - 31; http://dx.doi.org/10.4172/1948-5956.1000037
   Google Scholar
• Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell-surface proteins from live tumor cells stimulate anti-tumor immune response in vitro. Journal of Carcinogenesis & Mutagenesis. 2010; 1:1 - 3; http://dx.doi.org/10.4172/2157-2518.1000103
   Google Scholar
• Balashova EE, Dashtiev MI, Lokhov PG. Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence. Mol Cell Proteomics. 2012; 11:M111 014480.
   Google Scholar
• Lokhov P, Balashova E, Dashtiev M. Cell proteomic footprint. Rapid Commun Mass Spectrom 2009; 23:680 - 2; http://dx.doi.org/10.1002/rcm.3928; PMID: 19184978
   PubMedGoogle Scholar
• Paczesny S, Shi H, Saito H, Mannoni P, Fay J, Banchereau J, et al. Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. J Immunother 2005; 28:148 - 57; http://dx.doi.org/10.1097/01.cji.0000154247.97254.ef; PMID: 15725959
   PubMedGoogle Scholar
• Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86 - 94; http://dx.doi.org/10.1097/00002371-199508000-00002; PMID: 8574470
   PubMed Web of Science ®Google Scholar